All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

TARMAC: Can we combine targeted therapy with CAR T-cells in MCL?

Jan 9, 2023

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Adrian Minson, Peter MacCallum Cancer Centre, Melbourne, AU. We asked, Can we combine targeted therapy with chimeric antigen receptor (CAR) T-cell therapies in mantle cell lymphoma (MCL)?

TARMAC: Can we combine targeted therapy with CAR T-cells in MCL?

Minson explains why there is a drive to develop new therapies that will lead to more durable remissions in patients with MCL, and how immunotherapeutic agents, such as CAR T-cell therapies, have been beneficial but not without their challenges. Minson then reviews the positive impact of combining ibrutinib with CAR T-cell therapy and examines data on response, survival, and toxicity from the TARMAC trial (NCT04234061), in which this combination was used as a treatment option for MCL.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you